About Crescent Biopharma, Inc.
https://crescentbiopharma.comCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
CEO
Joshua T. Brumm
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-16 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FMR LLC
Shares:1.41M
Value:$17.87M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:1.39M
Value:$17.53M
VR ADVISER, LLC
Shares:1.39M
Value:$17.53M
Summary
Showing Top 3 of 52
About Crescent Biopharma, Inc.
https://crescentbiopharma.comCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $25.89M ▲ | $-24.61M ▼ | 0% | $-1.27K ▼ | $-24.58M ▼ |
| Q2-2025 | $0 | $21.03M ▲ | $-21.79M ▼ | 0% | $-0.56 ▼ | $-20.72M ▼ |
| Q1-2025 | $0 | $2.4M ▼ | $-2.34M ▲ | 0% | $-0.04 ▲ | $-2.4M ▲ |
| Q4-2024 | $0 | $7.33M ▼ | $-7.22M ▲ | 0% | $-0.11 ▲ | $-5.31M ▲ |
| Q3-2024 | $0 | $11.23M | $-9.82M | 0% | $-0.15 | $-5.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $133.26M ▼ | $138.27M ▼ | $21.63M ▲ | $116.64M ▼ |
| Q2-2025 | $152.65M ▲ | $157.43M ▲ | $18.18M ▲ | $139.25M ▲ |
| Q1-2025 | $5.61M ▼ | $5.99M ▼ | $2.62M ▼ | $3.38M ▼ |
| Q4-2024 | $10.72M ▼ | $11.09M ▼ | $5.78M ▲ | $5.31M ▼ |
| Q3-2024 | $14.39M | $15.7M | $4.32M | $11.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-24.61M ▼ | $-17.52M ▲ | $-586K ▼ | $-1.27M ▼ | $-19.38M ▼ | $-18.11M ▲ |
| Q2-2025 | $-21.79M ▼ | $-22.16M ▼ | $-140K ▼ | $145.39M ▲ | $147.03M ▲ | $-22.3M ▼ |
| Q1-2025 | $-2.34M ▲ | $-5.11M ▼ | $0 ▼ | $0 | $-5.11M ▼ | $-5.11M ▼ |
| Q4-2024 | $-37.88M ▼ | $-3.7M ▼ | $30K ▲ | $0 ▲ | $-3.67M ▲ | $-3.7M ▼ |
| Q3-2024 | $-2.63M | $19.4M | $9.97K | $-5.4K | $-22.39M | $19.41M |
Revenue by Products
| Product | Q2-2025 |
|---|---|
 Reportable Segment | $0 ▲ |
CEO
Joshua T. Brumm
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-16 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FMR LLC
Shares:1.41M
Value:$17.87M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:1.39M
Value:$17.53M
VR ADVISER, LLC
Shares:1.39M
Value:$17.53M
Summary
Showing Top 3 of 52